INCLUSION CRITERIA FOR SECOND-LINE THERAPY: For patients with known hepatic metastases, AST and ALT =< X the upper normal limit of institution's normal range INCLUSION CRITERIA FOR THIRD-LINE THERAPY: AST and ALT =< X the upper normal limit of institution's normal range INCLUSION CRITERIA FOR THIRD-LINE THERAPY: For patients with known hepatic metastases, AST and ALT =< X the upper normal limit of institution's normal range Patients with -hydroxyindoleacetic acid (HIAA) levels above or below the upper limit of normal range (normal: to mg/ hours) and those with unknown values at baseline are allowed to participate AST and ALT ? . X the upper normal limit of institution's normal range Total bilirubin ? . X the upper normal limit of institution's normal range PT and PTT must be ? . X upper normal limit of institution's normal range Aspartate aminotransferase (AST) and alanine aminotransferase (ALT) =< . x the upper normal limit of institution's normal range, at the time of enrollment; for subjects with liver metastases, AST and ALT =< x the upper normal limit of institution's normal range are acceptable as long as there is no persistent nausea, vomiting, right upper quadrant pain or tenderness, fever, rash, or eosinophilia Total bilirubin =< . x the upper normal limit of institution's normal range, at the time of enrollment; for subjects with liver metastases, total bilirubin > . - . x the upper normal limit of institution's normal range are acceptable as long as there is no persistent nausea, vomiting, right upper quadrant pain or tenderness, fever, rash, or eosinophilia Must have had an elevated serum CA level twice the upper limit of normal (per reference lab normal range) measured within weeks of enrollment. Aspartate aminotransferase (AST) and alanine aminotransferase (ALT) =< . x the upper normal limit of institution's normal range; for subjects with liver metastases, AST and ALT < x the upper normal limit of institution's normal range are acceptable as long as there is no persistent nausea, vomiting, right upper quadrant pain or tenderness, fever, rash, or eosinophilia Total bilirubin =< . x the upper normal limit of institution's normal range; for subjects with liver metastases, total bilirubin > . - . x the upper normal limit of institution's normal range are acceptable as long as there is no persistent nausea, vomiting, right upper quadrant pain or tenderness, fever, rash, or eosinophilia Bilirubin =< . X the upper normal limit of institution's normal range Partial thromboplastin time (PTT) must be =< X upper normal limit of institution's normal range; subjects on anticoagulant (such as coumadin) must have a PTT =< X upper normal limit of institution's normal range Non-fasting bilirubin =< . X the upper normal limit of institution's normal range Aspartate aminotransferase (AST) and alanine aminotransferase (ALT) =< . the upper normal limit of institution's normal range; for subjects with liver metastases, AST and ALT < the upper normal limit of institution's normal range AS LONG AS THERE IS NO persistent nausea, vomiting, right upper quadrant pain or tenderness, fever, rash, or eosinophilia Non-fasting direct bilirubin =< . the upper normal limit of institution's normal range Partial thromboplastin time (PTT) must be =< . upper normal limit of institution's normal range Aspartate aminotransferase (AST) and alanine aminotransferase (ALT) =< . the upper normal limit of institution's normal range; for subjects with liver metastases, AST and ALT < the upper normal limit of institution's normal range are acceptable AS LONG AS THERE IS NO persistent nausea, vomiting, right upper quadrant pain or tenderness, fever, rash, or eosinophilia; the combination of -FU and oxaliplatin is known to be safe to be administered in patients with such abnormal liver function tests Non-fasting direct bilirubin =< . the upper normal limit of institution's normal range; for subjects with liver metastases, non-fasting direct bilirubin > .-. x the upper normal limit of institution's normal range are acceptable AS LONG AS THERE IS NO persistent nausea, vomiting, right upper quadrant pain or tenderness, fever, rash, or eosinophilia; the combination of -FU and oxaliplatin is known to be safe to be administered in patients with such abnormal liver function tests Partial thromboplastin time (PTT) must be =< . upper normal limit of institution's normal range Aspartate aminotransferase (AST) and alanine aminotransferase (ALT) =< . X the upper normal limit of institution's normal range; for subjects with liver metastases, AST and ALT < X the upper normal limit of institution's normal range AS LONG AS THERE IS NO persistent nausea, vomiting, right upper quadrant pain or tenderness, fever, rash, or eosinophilia Non-fasting bilirubin =< . X the upper normal limit of institution's normal range; non-fasting bilirubin . - . X the upper normal limit of institution's normal range are acceptable AS LONG AS THERE IS NO persistent nausea, vomiting, right upper quadrant pain or tenderness, fever, rash, or eosinophilia Hepatic function: AST and ALT ? . the upper normal limit of institution's normal range. For subjects with liver metastases, AST and ALT ? the upper normal limit of institution's normal range; Bilirubin: ? . the upper normal limit of institution's normal range. Subjects have adequate bone marrow, renal, and hepatic function as follows: Bone marrow: Absolute neutrophil count (ANC) >/= ,/mm Platelets >/= ,/mm; Hemoglobin >/= . g/dL Renal function: Serum creatinine